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Abstract
Uncontrolled arterial pressure is associated with a fourfold increase in the risk of 
developing cardiovascular events compared to patients with hypertension who have 
reached the target blood pressure level. The aim of this study is to evaluate the charac-
teristics of patients with resistant arterial hypertension undergoing inpatient treatment 
at the Department of Symptomatic Hypertension and assess the prevalence of true 
resistant hypertension in a cohort of patients who take 3 and more antihypertensive 
agents, the clinical predictors of resistant hypertension. The study included 1146 
patients with resistant AH who received 3 or more antihypertensive drugs with the level 
of office blood pressure at admission ≥140/90 mm Hg. Patients were followed by the 
next examinations: body height and body measurements, office blood pressure, echo-
cardiography, sleep apnea determination, blood biochemical analysis, determination of 
levels of TTH, T3, T4, blood renin, blood aldosterone, metanephrine urine, and cortisol. 
Our data showed that 31% of patients who received 3 or more antihypertensive drugs 
had true resistant hypertension. Fixed combinations were taken by 71.9% of patients. 
We have found which factors were significantly associated with the treatment regimen 
with ≥3 or 4 drugs. Also we have demonstrated predictors for blood pressure reduction.
Keywords: resistant hypertension, pharmacology, predictors of resistance 
hypertension, target blood pressure, anti-hypertensive drugs
1. Background
The prevalence of resistant hypertension is very different according to dif-
ferent studies. In an analysis of National Health and Nutrition Examination 
Survey (NHANES) participants being treated for hypertension, only 53% were 
controlled to 140/90 mm Hg [1]. In Framingham Heart Study participants, only 
48% of treated patients were controlled to 140/90 mm Hg, and less than 40% of 
elderly participants (75 years of age) were at a goal blood pressure [2]. Among 
higher-risk populations and, in particular, with application of the lower goal blood 
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pressures recommended in the Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) 
for patients with diabetes mellitus or chronic kidney disease (CKD), the propor-
tion of uncontrolled patients is even higher. Of NHANES participants with chronic 
kidney disease, only 37% were controlled to 130/80 mm Hg3, and only 25% of 
participants with diabetes were controlled to 130/85 mm Hg [1, 3].
An estimated 10–30% of hypertensive patients are resistant to treatment defined as 
uncontrolled blood pressure (BP) with the use of ≥3 medications, including a diuretic 
[4–10]. A large number of studies have demonstrated that patients with resistant 
hypertension compared with patients with controlled hypertension have significantly 
a higher rate of target organ damage; increased cardiovascular risk, including coro-
nary heart disease, chronic kidney disease, congestive heart failure, and stroke; and a 
significantly poorer prognosis than those of nonresistant hypertensive patients [3, 11].
Poor medical adherence, poor blood pressure measuring technique, and white-
coat effect are relevant challenges to figuring out the real burden of resistant 
hypertension [11].
Previous studies have shown that obesity is associated with resistant AH [12]. 
In addition, other studies have shown that diabetes is associated with a resistant 
hypertension [13, 14]. Studies show that resistant AH is associated with an increase 
in age, female gender, Negroid race, the presence of diabetes mellitus, obesity, 
chronic kidney disease, and left ventricular hypertrophy [1, 10, 15–19]. For early 
detection of resistant AH, aggressive therapy can reduce both cardiovascular mor-
bidity and mortality. However, the exact prevalence of resistant AH is not known 
precisely because of its variety of definitions and diversity of study sites [20, 21].
Increased blood pressure is one of the most important risk factors for stroke [4, 6, 
22], and uncontrolled hypertension increases this risk [1, 23]. The prevalence of hyper-
tension in Asian countries is almost the same as in most developed countries; many 
Asian patients have uncontrolled hypertension compared with developed countries 
[24]. For example, in developed countries, blood pressure monitoring is about 52–60%, 
but in Malaysia, for example, this figure is 26% [2, 11, 24–26]. In Ukraine, blood pres-
sure control in the urban population is 14% and in rural populations 8% [27, 28].
In the current study, we have assessed the prevalence of true resistant hyper-
tension in a cohort of patients who take 3 and more antihypertensive agents, the 
clinical predictors of resistant hypertension.
2. Material and methods
The study included 1146 patients with resistant AH who received 3 or more 
antihypertensive drugs who were hospitalized in 2011–2015 at the Department of 
Symptomatic Hypertension at the Institute of Cardiology of Ukraine, Kyiv. The 
level of office blood pressure when admitted to the office when receiving 3 or more 
AH drugs was ≥140/90 mm Hg. The average systolic blood pressure (SBP)/diastolic 
blood pressure (DBP) was 174,60 ± 0,64/100,50 ± 0,38 mm Hg.
Inclusion criteria. The inclusion criteria are as follows: (1) men and women aged 
between 18 and 80 years old and (2) patients treated with 3 and more antihyperten-
sive drugs. The diagnosis of RH was made after treatment with three antihyperten-
sive drug classes at maximum tolerated doses for at least 6 months. The study did 
not include patients with acute myocardial infarction or cerebrovascular accidents 
less than 3 months, acute renal failure, decompensated liver disease (level of AST, 
ALT above 3 times upper limit of normal), pregnancy, or lactation.
Anthropometric measurements. Weight and height, measured by anthropomet-
ric scales, will be used to calculate the body mass index (BMI) using the formula 
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Parameters Value
Men, n (%) 423 (36,91%)
Women, n (%) 723 (63,09%)
Height, m 1,7 ± 0,01
Weight, kg 87,7 ± 0,61
Age, years 57,9 ± 0,37
BMI, kg/m2 31,0 ± 0,19
Office SBP mm Hg at hospitalization 174,6 ± 0,64
Office DBP mm Hg at hospitalization 100,5 ± 0,38
Office SBP mm Hg on discharge from hospital 131,3 ± 0,40
Office DBP mm Hg on discharge from hospital 80,1 ± 0,65
Index of apnea-hypopnea, events /h, (n = 75) 18,8 ± 2,11
AO, sm 3,4 ± 0,05
LA, sm 3,9 ± 0,06
Left ventricle end-systolic dimension, sm 3,5 ± 0,08
Left ventricle end-diastolic dimension, sm 5,5 ± 0,13
Left ventricle end-systolic volume, mL 48,3 ± 0,68
Left ventricle end-diastolic volume, mL 126,3 ± 1,17
Inter ventricular septum thickness, sm 1,2 ± 0,01
Left ventricle posterior wall thickness, sm 1,1 ± 0,01
EF, % 60,6 ± 0,23
Left ventricular mass index, g/m2 138,2 ± 1,43
K, mmol/l 5,1 ± 0,49
Na, mmol/l 144,0 ± 0,30
Bilirubin, μmol/l 14,1 ± 0,21
Creatinine, μmol/l 87,2 ± 0,58
CKD-EPI, ml/min/1.73 m2 82,7 ± 0,96
ALT, U/l 47,5 ± 3,39
AST, U/l 27,1 ± 0,71
Fasting glucose, mmol/l 6,0 ± 0,08
Uric acid, mmol/l (n = 850) 336,2 ± 3,62
Triiodothyronine (Т3), microU/l (n = 94) 4,6 ± 1,16
Thyroxin (Т4), microU/l (n = 111) 3,2 ± 0,67
Thyroid hormone (ТТН), microU/l (n = 231) 2,2 ± 0,15
Metanephrine urine, microG/24 h (n = 95) 124,5 ± 7,10
Renin, ng/l (n = 89) 155,2 ± 79,73
Aldosterone, ng/l (n = 118) 29,4 ± 2,90
Аldosterone-renin ratio, c.u. (n = 75) 3,3 ± 0,68
Cortisol, ng/l (n = 21) 108,0 ± 30,73
Total cholesterol, mmol/l 5,5 ± 0,04
Triglycerides, mmol/l 1,6 ± 0,04
HDL cholesterol, mmol/l 1,3 ± 0,02
LDL cholesterol, mmol/l 3,3 ± 0,07
VLDL cholesterol, mmol/l 0,7 ± 0,02
ІA (index of atherogenicity), c.u. 3,3 ± 0,07
Table 1. 
Clinical and demographic characteristics of the examined patients (n = 1146).
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BMI = weight (kg)/height squared (m2). BMIs of 18.5–26.9 kg/m2 are considered 
eutrophic values, while individuals with BMIs of 27.0–29.9 kg/m2 are overweight 
and ≥30 kg/m2 are obese.
All patients will undergo electrocardiography, echocardiography, and office-
measured SBP and DBP; an oscillometric device will be used to calculate the average 
of the three measurements. Biochemical and imaging tests. Blood samples will be 
drawn from all patients at the first visits after fasting for 12 h to measure serum 
total cholesterol, high-density lipoprotein cholesterol (HDLc), low-density lipopro-
tein cholesterol (LDLc), very low-density lipoprotein cholesterol (VLDLc), triglyc-
erides (TG), glucose, creatinine, sodium, and potassium; blood renin, aldosterone 
and aldosterone/renin ratio, metanephrines in urine, blood cortisol level, T3, T4, 
and TTH were determined in some patients. CKD-EPI was calculated. If needed, CT 
with intravenous contrast renal arteries and adrenal glands (for exclusion, second-
ary hypertension) and sleep apnea determination were performed on some patients 
(Table 1).
Statistical processing of the results was performed on a personal computer after 
creating databases in Microsoft Excel systems. The mean of the patients examined 
was determined using the analysis package in Microsoft Excel. All other statistical 
calculations were performed using SPSS 21.0. ANOVA to calculate the following 
parameters: the arithmetic mean value, M; the SD from the arithmetic mean value 
of m; and coefficient of reliability, p. The difference was considered reliable at a 
value of p < 0.05. The reliability of the difference between the groups was deter-
mined by the independent t-test for the mean. Correlation analysis was performed 
after determining the character of the distribution for Spearman.
3. Results
We examined 1146 patients who received 3 or more antihypertensive drugs. The 
mean age was 57,9 ± 0,37 years. The average body weight is 87,7 ± 0,61 kg. The aver-
age body mass index was 31,0 ± 0,19 kg/m2. Average baseline office SBP and DBP 
were 174,6 ± 0,64 and 100,5 ± 0,38 mm Hg accordingly.
Most of the patients received 3 antihypertensive drugs: 51.4%. 48.6% of the 
patients take four to six drugs. Most of them take four drugs, 37.1%, 9.1% five drugs, 
and 2.4% six drugs.
The frequency of appointment of different classes of antihypertensive agents in 
the examined patients is presented in Table 2. In the structure of the appointments 
of antihypertensive drugs (AHD), ACE inhibitors were prescribed more often, 
65.5%; calcium antagonists, 69.9%; and diuretics (loop, thiazide, and thiazide 
like), 91,8%. Beta-blockers were taken by 75.6% of patients and blockers to AT II 
receptor, 33.5%. Aldosterone receptor blockers were taken by 12.8% of patients and 
central activity drugs, 18.6%. Statins were taken by 63.8% of patients. Among those 
receiving combined therapy, most (71.9%) take fixed combinations. Attention was 
given to the low frequency of aldosterone receptor blockers received (12.8%), which 
was due to the fact that the study was conducted predominantly until the year 2015, 
when there was scientific evidence of the need for their use as the fourth drug.
For further analysis, we divided our patients according to the amount of drugs 
that they received. Although 3 or more antihypertensive drugs are used in the 
determination of resistant hypertension, we divided our patients into two groups: 
the first, those who took 3 drugs, and the second, those who took 4 or more drugs. 
A comparison of demographic characteristics and blood pressure levels in these 
groups is presented in Table 3.
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As can be seen from the table, the groups did not differ by age and sex on 
average, but patients taking ≥4 drugs had significantly higher body mass and BMI 
than the group of patients taking 3 drugs. They also had significantly higher levels 
of office BP, both when they arrived in the hospital and on discharge. It should be 
noted that in both groups the value of the apnea-hypopnea index was high but did 
not differ from each other.
According to laboratory tests, patients taking ≥4 drugs had significantly 
higher blood glucose levels—(6.20 ± 0.09) mmol—than patients taking 3 drugs, 
(5.90 ± 0.14) mmol (p < 0.05), and a higher level of renin plasma ((218.30 ± 15.73) 
vs. (31.10 ± 5.91) ng/l, (p < 0.05)). Renin-aldosterone ratio was almost twice as high 
Antihypertensive class %
Angiotensin-converting enzyme inhibitors 65,5
Angiotensinogen receptor blockers 33,5
Calcium channel blockers 69,9
Diuretics (thiazide, loops, thiazide like) 91,8
β-Blockers 75,6
Mineralocorticoid receptor antagonists 12,8
Central-acting agonists 18,6
α-Blockers 2,6
Fixed combination 71,9
Аcetylsalicylic acid 68,3
Statins 63,8
Table 2. 
Frequency of appointment of antihypertensive drugs of different classes among patients with resistant arterial 
hypertension (n = 1146).
Parameters Value P
3 drugs (n = 591) ≥4 drugs (n = 555)
Men/women, n (%) 231 (39,0)/360 (60,8) 192 (34,6)/363 (65,4) NS
Age, years 57,2 ± 0,54 58,7 ± 0,48 NS
Height, m 1,7 ± 0,01 1,7 ± 0,01 NS
Weight, kg 85,9 ± 0,85 89,3 ± 0,86 0,004
BMI, kg/m2 30,2 ± 0,26 31,6 ± 0,27 <0,001
Office SBP mm Hg at hospitalization 170,4 ± 0,79 179,0 ± 1,00 <0,001
Office DBP mm Hg at hospitalization 98,4 ± 0,48 102,6 ± 0,58 <0,001
Office SBP mm Hg on discharge from 
hospital
129,3 ± 0,52 133,5 ± 0,59 <0,001
Office DBP mm Hg on discharge from 
hospital
78,5 ± 0,33 81,8 ± 1,29 0,013
Index of apnea-hypopnea, events/h* 18,7 ± 3,07 18,9 ± 2,90 NS
*The somnography was performed in 31 patients in the first group and in 44 patients in the second group.
Table 3. 
Characteristics of patients, depending on the number of prescribed antihypertensive drugs (n = 1146).
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(3.90 ± 0.95 vs. 2.20 ± 0.65 U/d), although it did not differ significantly between 
patient groups.
Analyzing the differences between patients in both groups in the main clinical 
states, we found that in patients receiving 4 or more drugs, significantly more 
obesity (45.6 vs. 34.0%), more often secondary hypertension (5.4 against 2.5%) 
due to stenosis of the renal arteries (1.6 vs. 0.2%), and hyperaldosteronism (2.3 
vs. 0.2%) were observed; type II diabetes mellitus was more frequent (24.7 vs. 
9, 5%); pathology of the thyroid gland (12.6 vs. 8.4%) due to hypothyroidism 
(4.1 vs. 1.5%) and chronic kidney disease were more common (5.0 vs. 1.5%); and 
chronic pyelonephritis (18.9 vs. 14.0%), ischemic heart disease (IHD) (47.0 vs. 
37.2%) with angina pectoris III (7.7 vs. 3.4%), and heart failure (15.0 vs. 9.3%) 
were observed.
In analyzing the degree of decrease in blood pressure, we found that, in general, 
the reduction of office blood pressure among patients receiving 3 or more drugs 
was for SBP (43,47 ± 0,65) mm Hg and for DBP (20,33 ± 0.74) mm Hg, p < 0.001 for 
both values.
The analysis of the degree of reduction of blood pressure, depending on the 
amount of drugs, showed that DBP between patients taking 3 and 4 or more drugs 
did not differ significantly, 19.88 versus 20.81 mm Hg, respectively, and office SBP 
significantly lowered in patients taking 4 or more drugs at 45.78 mm Hg vs. group 
taking 3 drugs—41.3 mm Hg, p < 0.001.
Among all patients (n = 1146), 355 (31%) did not reach the target blood pressure 
level. Patients who did not achieve targeted SBP (31%) had significantly higher 
blood pressure when inpatient. They had a significantly higher blood cortisol 
SBP on discharge DBP on discharge
Age β = −0,089 Р < 0,001 β = −0,196 Р < 0,001
Gender β = 0,125 Р < 0,001 β = 0,130 Р < 0,001
Weight β = 0,106 Р = 0,004 β = 0,127 Р < 0,001
BMI β = −0,202 Р = 0,010
Arterial hypertension β = 0,205 Р = 0,001 β = 0,117 Р < 0,001
Arterial hypertension II β = 0,108 Р = 0,001 β = 0,133 Р < 0,001
Arterial hypertension III β = −0,259 Р = 0,023 β = −0,106 Р = 0,001
Secondary arterial hypertension β = −0,096 Р = 0,006 β = −0,114 Р < 0,001
Vasorenal arterial hypertension β = −0,082 Р = 0,011 β = −0,101 Р = 0,002
Hyperaldosteronism β = −0,103 Р = 0,022 β = −0,071 Р = 0,027
Pituitary adenoma β = −0,089 Р = 0,006
Heart failure β = 0,146 Р < 0,001
Heart failure II β = −0,079 Р = 0,014 β = −0,103 Р = 0,002
Adrenal pathology β = −0,065 Р = 0,043 β = −0,070 Р = 0,029
Т4 β = −0,230 Р = 0,020 β = −0,219 Р = 0,027
Interventricular septum thickness β = 0,214 Р = 0,027 β = 0,154 Р < 0,001
HD cholesterol β = −0,230 Р = 0,001 β = −0,198 Р = 0,003
Calcium channel blockers β = −0,140 Р < 0,001 β = −0,080 Р = 0,013
Central-acting agonists β = −0,214 Р < 0,001 β = −0,137 Р < 0,001
Mineralocorticoid receptor antagonists β = −0,101 Р = 0,002 β = −0,096 Р = 0,005
Аcetylsalicylic acid β = 0,169 Р < 0,001 β = 0,197 Р < 0,001
Table 4. 
Factors influencing the reduction of blood pressure on discharge from the hospital (n = 1146).
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level (155.0 ± 44.0 vs. 35.9 ± 20.8 ng/l) and the highest left ventricular mass index 
(147.5 ± 3.46 vs. 135.3 ± 1.74 g/m2), and obesity (42.9 vs. 37.5%), kidney abnormality 
(2.7 vs. 0.8%), obliterative lower extremity atherosclerosis (2.0 vs. 0.2%), struc-
tural alterations in the adrenal gland (3.0 vs. 1.2%), nephropathy (1.3 vs. 0.2%), 
and higher heart failure (HF in the 16.9 vs. 8.5%) were more common.
When we performed a regression analysis, we found that the decrease in office 
systolic and diastolic blood pressure depended on age, sex, and body weight. Thus, 
office SBP/DBP was worse in men; patients with a younger age; patients with 
greater body mass, with hypertension III degree, and with secondary hypertension, 
especially with hyperaldosteronism and vasorenal hypertension, adrenal pathology, 
heart failure, lower T4 hormone levels, more low levels of HDL cholesterol, and a 
larger thickness of interventricular septum thickness; and patients receiving less 
calcium antagonists, centrally acting drugs, and aldosterone antagonists. Data are 
presented in Table 4.
Table 5 presents the results of a regression analysis for the detection of predic-
tors of resistance hypertension in patients receiving 3 or more antihypertensive 
drugs. The predictors for blood pressure reduction were male sex, left ventricular 
mass index, interventricular septum thickness, left ventricle posterior wall thick-
ness, hypothyroidism, the presence of chronic kidney disease, CKD-EPI level, blood 
creatinine levels, the presence of heart failure, the presence of secondary hyperten-
sion, hyperaldosteronism, pituitary adenoma, and vasorenal hypertension.
Variables Predictors of failure to reach the target BP
Gender β = 0,119 Р < 0,001
Left ventricular mass index β = 0,139 Р = 0,001
Inter ventricular septum thickness β = 0,169 Р = 0,002
Left ventricle posterior wall thickness β = 0,147 Р < 0,001
Arterial hypertension β = 0,085 Р = 0,009
Arterial hypertension II β = 0,090 Р = 0,005
Arterial hypertension III β = 0,077 Р = 0,018
Secondary arterial hypertension β = 0,075 Р = 0,020
Vasorenal arterial hypertension β = 0,107 Р = 0,001
Hyperaldosteronism β = 0,064 Р = 0,049
Pituitary adenoma β = 0,068 Р = 0,036
Pathology of the thyroid gland β = 0,102 Р = 0,002
Hypothyroidism β = 0,069 Р = 0,031
Mixed goiter β = 0,072 Р = 0,024
Heart failure II β = 0,125 Р < 0,001
Chronic kidney disease β = 0,076 Р = 0,018
Creatinine β = 0,108 Р = 0,028
CKD-EPI β = 0,135 Р = 0,025
Office SBP mm Hg at hospitalization β = 0,368 Р < 0,001
Office DBP mm Hg at hospitalization β = 0,238 Р < 0,001
Calcium channel blockers β = −0,116 Р = 0,001
Central-acting agonists β = −0,146 Р < 0,001
Fixed combinations β = 0,098 Р = 0,003
Аcetylsalicylic acid β = 0,103 Р = 0,002
Table 5. 
Predictors of resistance hypertension in patients receiving 3 or more antihypertensive drugs (n = 1146).
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4. Discussion
Our data showed that in patients who received 3 or more antihypertensive drugs 
in 31%, the goal blood pressure (<140/90 mm Hg) was not reached, meaning it was 
true resistant hypertension. This is possible somewhat more than in other studies, 
but we have a specialized department, which is directed precisely by patients who 
failed to reach the target levels of blood pressure at the outpatient stage.
Among our patients with resistant arterial hypertension, 3 antihypertensive 
drugs were received by 51.4% of patients, 4 antihypertensive drugs were taken by 
37.1% of patients, 5 antihypertensive drugs were taken by 9.1% of patients, and 6 
antihypertensive drugs were taken by 2.4% of patients.
In our study ACE inhibitors were more often prescribed in 65.5% of patients, 
calcium antagonists in 69.9% of patients, and diuretics in 91.8% of patients. Beta-
adrenergic blockers were administered to 75.5% of patients, receptor blockers to AT 
II to 33.5% of patients, and aldosterone receptor blockers to 12.8% of patients. Fixed 
combinations were taken by 71.9% of patients.
In our study patients who did not achieve targeted SBP (31%) had significantly 
higher blood pressure when inpatient. They had a significantly higher blood cortisol 
level (155.0 ± 44.0 vs. 35.9 ± 20.8 ng/l) and the highest left ventricular mass index 
(147.5 ± 3.46 vs. 135.3 ± 1.74 g/m2), and obesity (42.9 vs. 37.5%), kidney abnormality 
(2.7 vs. 0.8%), obliterative lower extremity atherosclerosis (2.0 vs. 0.2%), struc-
tural alterations in the adrenal gland (3.0 vs. 1.2%), nephropathy (1.3 vs. 0.2%), 
and more often heart failure (16.9 vs. 8.5%) were more common.
In our study, patients taking ≥4 drugs had significantly higher blood glucose 
levels—(6.20 ± 0.09) mmol/l—than patients taking 3 drugs, (5.90 ± 0.14) mmol/l 
(p < 0.05), and the highest level of renin plasma ((218.30 ± 15.73) vs. (31.10 ± 5.91) 
ng/l (p < 0.05)). Renin-aldosterone ratio was almost twice as high (3.90 ± 0.95 vs. 
2.20 ± 0.65 U/d), although it did not differ significantly between patient groups.
Yook Chin Chia and Siew Mooi Ching studied the prevalence and predictors 
of resistance to hypertension in Southeast Asia [24]. The prevalence of resistant 
hypertension in the primary examination in their study was 8.8%. Their data also 
show that patients with chronic kidney disease were 2.9-fold more likely to develop 
resistant AH than in patients without CKD. This is consistent with the findings in 
other studies [25, 29]. In our study, CKD-EPI and CKD were predictors of resistance 
hypertension.
The authors explain this by the fact that in patients with CKD, there is increased 
sensitivity to salt, resulting in a delay in sodium and fluid, which leads to more 
complex control of blood pressure [24]. Patients in the Yook Chin Chia study were 
aged 66.9 years. In our study, patients were more younger, 57,9 ± 0,37. Resistant 
hypertension in Yook Chin Chia study was negatively related to age, which the 
authors explain with the effect of survival of patients who were treated compared 
with those patients who already had complications from uncontrolled hypertension. 
In our study, office SBP/DBP was worse in younger age patients.
Many studies have shown that most patients with hypertension need 2 or more 
drugs to achieve the target blood pressure [2, 30–34]. The average number of 
AH drugs used in their study was 2. They also showed poor monitoring of blood 
pressure among those taking only 2 drugs; even in those who received 3 drugs, the 
level of blood pressure control was less than 50%. However, in general, the use of 
diuretics in their study was low.
Holmqvist et al. studied the adherence to treatment in patients with resistance to 
hypertension, which controlled or did not control blood pressure and what factors 
contributed to nonadherence to treatment. 5846 patients received treatment with 
3 or more AH drugs for 2 years [26]. Patients who achieved target blood pressure 
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levels were older in age and among them those with diabetes were fewer. Initially, 
patients had an adherence above 80%. During the first year of treatment, the adher-
ence decreased by 11%, regardless of whether it was controlled or not controlled. 
The highest adherence was observed only in patients with diabetes mellitus and 
hypertension, in which the authors explain the structuring of the treatment of such 
a patient.
Resistant hypertension is associated with significant adverse effects, includ-
ing an increased risk of cardiovascular events and death as well as a decrease in 
the quality of life [22, 24]. The exact mechanisms underlying the development of 
resistant hypertension remain unclear, although several mechanisms were proposed 
[8, 9, 35, 36]. An increase in fluid content and an increase in the level of aldosterone 
play a crucial role in the development of resistance hypertension, whereas enhanced 
activation of the sympathoadrenal system significantly contributes to refractory 
hypertension [14, 20, 34].
In conclusion, the predictors for blood pressure reduction were male sex, left 
ventricular mass index, interventricular septum thickness, left ventricle posterior 
wall thickness, the presence of chronic kidney disease, CKD-EPI level, blood 
creatinine levels, and the presence of heart failure.
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